vs

Side-by-side financial comparison of Hilltop Holdings Inc. (HTH) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $300.5M, roughly 1.1× Hilltop Holdings Inc.). Hilltop Holdings Inc. runs the higher net margin — 13.0% vs -18.2%, a 31.2% gap on every dollar of revenue.

Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

HTH vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.1× larger
MDGL
$321.1M
$300.5M
HTH
Higher net margin
HTH
HTH
31.2% more per $
HTH
13.0%
-18.2%
MDGL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
HTH
HTH
MDGL
MDGL
Revenue
$300.5M
$321.1M
Net Profit
$39.0M
$-58.6M
Gross Margin
Operating Margin
-18.6%
Net Margin
13.0%
-18.2%
Revenue YoY
210.8%
Net Profit YoY
-12.4%
1.4%
EPS (diluted)
$0.64
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HTH
HTH
MDGL
MDGL
Q1 26
$300.5M
Q4 25
$329.9M
$321.1M
Q3 25
$330.2M
$287.3M
Q2 25
$303.3M
$212.8M
Q1 25
$318.5M
$137.3M
Q4 24
$301.1M
$103.3M
Q3 24
$305.5M
$62.2M
Q2 24
$297.0M
Net Profit
HTH
HTH
MDGL
MDGL
Q1 26
$39.0M
Q4 25
$41.6M
$-58.6M
Q3 25
$45.8M
$-114.2M
Q2 25
$36.1M
$-42.3M
Q1 25
$42.1M
$-73.2M
Q4 24
$35.5M
$-59.4M
Q3 24
$29.7M
$-107.0M
Q2 24
$20.3M
Gross Margin
HTH
HTH
MDGL
MDGL
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Operating Margin
HTH
HTH
MDGL
MDGL
Q1 26
Q4 25
16.1%
-18.6%
Q3 25
18.4%
-39.7%
Q2 25
16.3%
-22.2%
Q1 25
18.1%
-57.8%
Q4 24
14.7%
-64.8%
Q3 24
13.9%
-187.1%
Q2 24
10.0%
Net Margin
HTH
HTH
MDGL
MDGL
Q1 26
13.0%
Q4 25
12.6%
-18.2%
Q3 25
13.9%
-39.8%
Q2 25
11.9%
-19.9%
Q1 25
13.2%
-53.4%
Q4 24
11.8%
-57.5%
Q3 24
9.7%
-172.0%
Q2 24
6.8%
EPS (diluted)
HTH
HTH
MDGL
MDGL
Q1 26
$0.64
Q4 25
$0.68
$-2.55
Q3 25
$0.74
$-5.08
Q2 25
$0.57
$-1.90
Q1 25
$0.65
$-3.32
Q4 24
$0.55
$-2.50
Q3 24
$0.46
$-4.92
Q2 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HTH
HTH
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$198.7M
Total DebtLower is stronger
$990.8M
$339.9M
Stockholders' EquityBook value
$2.2B
$602.7M
Total Assets
$15.7B
$1.3B
Debt / EquityLower = less leverage
0.46×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HTH
HTH
MDGL
MDGL
Q1 26
Q4 25
$198.7M
Q3 25
$295.7M
Q2 25
$186.2M
Q1 25
$183.6M
Q4 24
$100.0M
Q3 24
$232.7M
Q2 24
Total Debt
HTH
HTH
MDGL
MDGL
Q1 26
$990.8M
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Stockholders' Equity
HTH
HTH
MDGL
MDGL
Q1 26
$2.2B
Q4 25
$2.2B
$602.7M
Q3 25
$2.2B
$625.7M
Q2 25
$2.2B
$696.0M
Q1 25
$2.2B
$710.6M
Q4 24
$2.2B
$754.4M
Q3 24
$2.2B
$777.2M
Q2 24
$2.1B
Total Assets
HTH
HTH
MDGL
MDGL
Q1 26
$15.7B
Q4 25
$15.8B
$1.3B
Q3 25
$15.6B
$1.4B
Q2 25
$15.4B
$1.0B
Q1 25
$15.8B
$996.6M
Q4 24
$16.3B
$1.0B
Q3 24
$15.9B
$1.1B
Q2 24
$15.6B
Debt / Equity
HTH
HTH
MDGL
MDGL
Q1 26
0.46×
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HTH
HTH
MDGL
MDGL
Operating Cash FlowLast quarter
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HTH
HTH
MDGL
MDGL
Q1 26
Q4 25
$-38.7M
$-133.5M
Q3 25
$273.0M
$79.8M
Q2 25
$-234.6M
$-47.1M
Q1 25
$5.8M
$-88.9M
Q4 24
$273.9M
$-104.5M
Q3 24
$515.6M
$-67.0M
Q2 24
$-435.3M
Free Cash Flow
HTH
HTH
MDGL
MDGL
Q1 26
Q4 25
$-55.5M
$-133.8M
Q3 25
$271.0M
$79.0M
Q2 25
$-234.6M
Q1 25
$5.0M
Q4 24
$266.8M
$-104.7M
Q3 24
$513.8M
$-67.8M
Q2 24
$-437.3M
FCF Margin
HTH
HTH
MDGL
MDGL
Q1 26
Q4 25
-16.8%
-41.7%
Q3 25
82.1%
27.5%
Q2 25
-77.4%
Q1 25
1.6%
Q4 24
88.6%
-101.3%
Q3 24
168.2%
-109.0%
Q2 24
-147.2%
Capex Intensity
HTH
HTH
MDGL
MDGL
Q1 26
Q4 25
5.1%
0.1%
Q3 25
0.6%
0.3%
Q2 25
0.0%
0.0%
Q1 25
0.3%
0.0%
Q4 24
2.4%
0.2%
Q3 24
0.6%
1.3%
Q2 24
0.7%
Cash Conversion
HTH
HTH
MDGL
MDGL
Q1 26
Q4 25
-0.93×
Q3 25
5.96×
Q2 25
-6.50×
Q1 25
0.14×
Q4 24
7.71×
Q3 24
17.36×
Q2 24
-21.41×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HTH
HTH

Noninterest Income$188.4M63%
Net Interest Income$112.1M37%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons